Therapeutic potential of nuclear receptor agonists in Alzheimer's disease

Brookmeyer, 2007, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement., 3, 186, 10.1016/j.jalz.2007.04.381

Selkoe, 2016, The amyloid hypothesis of Alzheimer's disease at 25 years, EMBO Mol. Med., 8, 595, 10.15252/emmm.201606210

Serrano-Pozo, 2011, Neuropathological alterations in Alzheimer disease, Cold Spring Harb. Perspect. Med., 1, a006189, 10.1101/cshperspect.a006189

Kummer, 2014, Truncated and modified amyloid-beta species, Alzheimers Res. Ther., 6, 28, 10.1186/alzrt258

Chow, 2010, An overview of APP processing enzymes and products, Neuromolecular Med., 12, 1, 10.1007/s12017-009-8104-z

Mawuenyega, 2010, Decreased clearance of CNS beta-amyloid in Alzheimer's disease, Science., 330, 1774, 10.1126/science.1197623

Castellano, 2011, Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance, Sci. Transl. Med., 3, 89ra57, 10.1126/scitranslmed.3002156

Yuan, 2016, Attenuation of beta-amyloid deposition and neurotoxicity by chemogenetic modulation of neural activity, J. Neurosci., 36, 632, 10.1523/JNEUROSCI.2531-15.2016

Sturchler-Pierrat, 1997, Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology, Proc. Natl. Acad. Sci. USA., 94, 13287, 10.1073/pnas.94.24.13287

Hsiao, 1996, Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice, Science., 274, 99, 10.1126/science.274.5284.99

Moechars, 1999, Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain, J. Biol. Chem., 274, 6483, 10.1074/jbc.274.10.6483

Mucke, 2000, High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation, J. Neurosci., 20, 4050, 10.1523/JNEUROSCI.20-11-04050.2000

Chishti, 2001, Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695, J. Biol. Chem., 276, 21562, 10.1074/jbc.M100710200

Borchelt, 1997, Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins, Neuron., 19, 939, 10.1016/S0896-6273(00)80974-5

Jankowsky, 2004, Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase, Hum. Mol. Genet., 13, 159, 10.1093/hmg/ddh019

Oakley, 2006, Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation, J. Neurosci., 26, 10129, 10.1523/JNEUROSCI.1202-06.2006

Yoshiyama, 2007, Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model, Neuron., 53, 337, 10.1016/j.neuron.2007.01.010

Oddo, 2003, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron., 39, 409, 10.1016/S0896-6273(03)00434-3

Billings, 2005, Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice, Neuron., 45, 675, 10.1016/j.neuron.2005.01.040

Evans, 2014, Nuclear receptors, RXR, and the big bang, Cell., 157, 255, 10.1016/j.cell.2014.03.012

Sever, 2013, Signaling by nuclear receptors, Cold Spring Harb. Perspect. Biol., 5, a016709, 10.1101/cshperspect.a016709

Dawson, 2012, The retinoid X receptors and their ligands, Biochim. Biophys. Acta., 1821, 21, 10.1016/j.bbalip.2011.09.014

Glass, 2010, Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells, Nat. Rev. Immunol., 10, 365, 10.1038/nri2748

Whitney, 2002, Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system, Mol. Endocrinol., 16, 1378, 10.1210/mend.16.6.0835

Wang, 2002, Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration, Proc. Natl. Acad. Sci. USA., 99, 13878, 10.1073/pnas.172510899

Andersson, 2005, Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice, Proc. Natl. Acad. Sci. USA., 102, 3857, 10.1073/pnas.0500634102

Wang, 2010, PPARs: diverse regulators in energy metabolism and metabolic diseases, Cell Res., 20, 124, 10.1038/cr.2010.13

Warden, 2016, Localization of PPAR isotypes in the adult mouse and human brain, Sci. Rep., 6, 27618, 10.1038/srep27618

Moreno, 2004, Immunolocal­ization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS, Neuroscience., 123, 131, 10.1016/j.neuroscience.2003.08.064

Heneka, 2007, PPARs in the brain, Biochim. Biophys. Acta., 1771, 1031, 10.1016/j.bbalip.2007.04.016

Kapadia, 2008, Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists, Front. Biosci., 13, 1813, 10.2741/2802

Quintanilla, 2014, Role of PPAR gamma in the differentiation and function of neurons, PPAR Res., 2014, 768594, 10.1155/2014/768594

Chakravarthy, 2007, Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis, J. Clin. Invest., 117, 2539, 10.1172/JCI31183

Roy, 2015, HMG-CoA reductase inhibitors bind to PPARalpha to upregulate neurotrophin expression in the brain and improve memory in mice, Cell Metab., 22, 253, 10.1016/j.cmet.2015.05.022

Fidaleo, 2014, Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARalpha) and its lipid ligands, Curr. Med. Chem., 21, 2803, 10.2174/0929867321666140303143455

Hall, 2008, Peroxisome proliferator-activated receptor beta/delta in the brain: facts and hypothesis, PPAR Res., 2008, 780452, 10.1155/2008/780452

Lane, 2005, Role of retinoid signalling in the adult brain, Prog. Neurobiol., 75, 275, 10.1016/j.pneurobio.2005.03.002

Ransom, 2014, The rhythm of retinoids in the brain, J. Neurochem., 129, 366, 10.1111/jnc.12620

Krezel, 1999, Differential expression of retinoid receptors in the adult mouse central nervous system, Neuroscience., 89, 1291, 10.1016/S0306-4522(98)00342-X

Arfaoui, 2013, Expression of retinoic acid receptors and retinoid X receptors in normal and vitamin A deficient adult rat brain, Ann. Anat., 195, 111, 10.1016/j.aanat.2012.06.006

Chiang, 1998, An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression, Neuron., 21, 1353, 10.1016/S0896-6273(00)80654-6

Sarti, 2012, Conditional RARalpha knockout mice reveal acute requirement for retinoic acid and RARalpha in homeostatic plasticity, Front. Mol. Neurosci., 5, 16, 10.3389/fnmol.2012.00016

IJpenberg, 2004, In vivo activation of PPAR target genes by RXR homodimers, EMBO J., 23, 2083, 10.1038/sj.emboj.7600209

Núñez, 2010, Retinoid X receptor alpha controls innate inflammatory responses through the up-regulation of chemokine expression, Proc. Natl. Acad. Sci. USA., 107, 10626, 10.1073/pnas.0913545107

Tanaka, 2007, p21WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid X receptor (RXR) heterodimer and RXR/RXR homodimer, J. Biol. Chem., 282, 29987, 10.1074/jbc.M701700200

Desvergne, 2007, RXR: from partnership to leadership in metabolic regulations, Vitam. Horm., 75, 1, 10.1016/S0083-6729(06)75001-4

Holtzman, 2001, Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy, J. Mol. Neurosci., 17, 147, 10.1385/JMN:17:2:147

Zhang, 2015, Cholesterol metabolism and homeostasis in the brain, Protein Cell., 6, 254, 10.1007/s13238-014-0131-3

Liang, 2004, A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes, J. Neurochem., 88, 623, 10.1111/j.1471-4159.2004.02183.x

Jiang, 2008, ApoE promotes the proteolytic degradation of Abeta, Neuron., 58, 681, 10.1016/j.neuron.2008.04.010

Cramer, 2012, ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models, Science., 335, 1503, 10.1126/science.1217697

Mandrekar-Colucci, 2012, Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease, J. Neurosci., 32, 10117, 10.1523/JNEUROSCI.5268-11.2012

Du, 2009, PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons, Biochem. Biophys. Res. Commun., 383, 485, 10.1016/j.bbrc.2009.04.047

Espuny-Camacho, 2010, Peroxisome proliferator-activated receptor gamma enhances the activity of an insulin degrading enzyme-like metalloprotease for amyloid-beta clearance, J. Alzheimers Dis., 20, 1119, 10.3233/JAD-2010-091633

Kalinin, 2009, A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease, Curr. Alzheimer Res., 6, 431, 10.2174/156720509789207949

Goncalves, 2013, Amyloid beta inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor alpha agonist, Eur. J. Neurosci., 37, 1182, 10.1111/ejn.12142

Savage, 2015, Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease, J. Neurosci., 35, 6532, 10.1523/JNEUROSCI.4586-14.2015

Yamanaka, 2012, PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice, J. Neurosci., 32, 17321, 10.1523/JNEUROSCI.1569-12.2012

Terwel, 2011, Critical role of astroglial apolipoprotein E and liver X receptor-alpha expression for microglial Abeta phagocytosis, J. Neurosci., 31, 7049, 10.1523/JNEUROSCI.6546-10.2011

Hjorth, 2013, Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-beta42 by human microglia and decrease inflammatory markers, J. Alzheimers Dis., 35, 697, 10.3233/JAD-130131

Corbett, 2015, Activation of peroxisome proliferator-activated receptor alpha stimulates ADAM10-mediated proteolysis of APP, Proc. Natl. Acad. Sci. USA., 112, 8445, 10.1073/pnas.1504890112

Sastre, 2006, Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma, Proc. Natl. Acad. Sci. USA., 103, 443, 10.1073/pnas.0503839103

Zhang, 2014, Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease, J. Neurosci., 34, 14919, 10.1523/JNEUROSCI.1165-14.2014

Katsouri, 2011, PPARgamma co-activator-1alpha (PGC-1alpha) reduces amyloid-beta generation through a PPARgamma-dependent mechanism, J. Alzheimers Dis., 25, 151, 10.3233/JAD-2011-101356

Blondrath, 2016, The nuclear cofactor receptor interacting protein-140 (RIP140) regulates the expression of genes involved in Abeta generation, Neurobiol. Aging., 47, 180, 10.1016/j.neurobiolaging.2016.08.003

Sun, 2003, Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion, J. Biol. Chem., 278, 27688, 10.1074/jbc.M300760200

Koldamova, 2005, The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease, J. Biol. Chem., 280, 4079, 10.1074/jbc.M411420200

Heneka, 2015, Neuroinflammation in Alzheimer's disease, Lancet Neurol., 14, 388, 10.1016/S1474-4422(15)70016-5

Cameron, 2010, Inflammation, microglia, and Alzheimer's disease, Neurobiol. Dis., 37, 503, 10.1016/j.nbd.2009.10.006

Colton, 2006, Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD, J. Neuroinflammation., 3, 27, 10.1186/1742-2094-3-27

Lee, 2009, Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes, Mol. Cell., 35, 806, 10.1016/j.molcel.2009.07.021

Zelcer, 2007, Attenuation of neuroinflammation and Alzheimer's disease pathology by liver X receptors, Proc. Natl. Acad. Sci. USA., 104, 10601, 10.1073/pnas.0701096104

Mounier, 2015, Bexarotene-activated retinoid X receptors regulate neuronal differentiation and dendritic complexity, J. Neurosci., 35, 11862, 10.1523/JNEUROSCI.1001-15.2015

Nam, 2016, RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Abeta oligomers, Sci. Rep., 6, 24048, 10.1038/srep24048

Boehm-Cagan, 2014, Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene, J. Neurosci., 34, 7293, 10.1523/JNEUROSCI.5198-13.2014

Sandoval-Hernández, 2016, Liver X receptor agonist modifies the DNA methylation profile of synapse and neurogenesis-related genes in the triple transgenic mouse model of Alzheimer's disease, J. Mol. Neurosci., 58, 243, 10.1007/s12031-015-0665-8

Sandoval-Hernández, 2015, Role of liver X receptor in AD pathophysiology, PLoS One., 10, e0145467, 10.1371/journal.pone.0145467

Rodriguez-Rivera, 2011, Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status, Behav. Brain Res., 216, 255, 10.1016/j.bbr.2010.08.002

Denner, 2012, Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways, J. Neurosci., 32, 16725, 10.1523/JNEUROSCI.2153-12.2012

Jahrling, 2014, PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement, J. Neurosci., 34, 4054, 10.1523/JNEUROSCI.4024-13.2014

Nenov, 2014, Cognitive enhancing treatment with a PPARgamma agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice, J. Neurosci., 34, 1028, 10.1523/JNEUROSCI.3413-13.2014

Nenov, 2015, Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPARgamma agonism, J. Neurophysiol., 113, 1712, 10.1152/jn.00419.2014

Xu, 2014, Rosiglitazone prevents amyloid-beta oligomer-induced impairment of synapse formation and plasticity via increasing dendrite and spine mitochondrial number, J. Alzheimers Dis., 39, 239, 10.3233/JAD-130680

Santos, 2005, Peroxisomal proliferation protects from beta-amyloid neurodegeneration, J. Biol. Chem., 280, 41057, 10.1074/jbc.M505160200

Inestrosa, 2005, Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling, Exp. Cell Res., 304, 91, 10.1016/j.yexcr.2004.09.032

Mariani, 2017, Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease, Sci. Rep., 7, 42270, 10.1038/srep42270

Malm, 2015, Activation of the nuclear receptor PPARdelta is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation, J. Neuroinflammation., 12, 7, 10.1186/s12974-014-0229-9

Katsuki, 2009, Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling, J. Neurochem., 110, 707, 10.1111/j.1471-4159.2009.06171.x

Gold, 2010, Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study, Dement. Geriatr. Cogn. Disord., 30, 131, 10.1159/000318845

Heneka, 2015, Effect of pioglitazone medication on the incidence of dementia, Ann. Neurol., 78, 284, 10.1002/ana.24439

Cummings, 2016, Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease, Alzheimers Res. Ther., 8, 4, 10.1186/s13195-016-0173-2

Ghosal, 2016, A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects, Alzheimers Dement., 2, 110, 10.1016/j.trci.2016.06.001

Yan, 2003, Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease, J. Neurosci., 23, 7504, 10.1523/JNEUROSCI.23-20-07504.2003

Lacombe, 2004, Effect of anti-inflammatory agents on transforming growth factor beta over-expressing mouse brains: a model revised, J. Neuroinflammation., 1, 11, 10.1186/1742-2094-1-11

Heneka, 2005, Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice, Brain., 128, 1442, 10.1093/brain/awh452

Nicolakakis, 2008, Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, J. Neurosci., 28, 9287, 10.1523/JNEUROSCI.3348-08.2008

Searcy, 2012, Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease, J. Alzheimers Dis., 30, 943, 10.3233/JAD-2012-111661

Masciopinto, 2012, Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice, Cell Death Dis., 3, e448, 10.1038/cddis.2012.189

Papadopoulos, 2013, Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology, PLoS One., 8, e68612, 10.1371/journal.pone.0068612

Prakash, 2014, Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of beta-amyloid animal model of Alzheimer's disease, Neurotox. Res., 25, 335, 10.1007/s12640-013-9437-9

Skerrett, 2015, Combined liver X receptor/peroxisome proliferator-activated receptor gamma agonist treatment reduces amyloid beta levels and improves behavior in amyloid precursor protein/presenilin 1 mice, J. Biol. Chem., 290, 21591, 10.1074/jbc.M115.652008

Toba, 2016, PPARgamma agonist pioglitazone improves cerebellar dysfunction at pre-Abeta deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice, Biochem. Biophys. Res. Commun., 473, 1039, 10.1016/j.bbrc.2016.04.012

Pedersen, 2006, Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice, Exp. Neurol., 199, 265, 10.1016/j.expneurol.2006.01.018

Escribano, 2009, Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model, Biochem. Biophys. Res. Commun., 379, 406, 10.1016/j.bbrc.2008.12.071

Toledo, 2010, Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease, Mol. Psychiatry., 15, 272, 10.1038/mp.2009.72

Escribano, 2010, Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology, Neuropsychopharmacology., 35, 1593, 10.1038/npp.2010.32

O'Reilly, 2012, Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP/PS1 mice, J. Neuroimmune Pharmacol., 7, 140, 10.1007/s11481-011-9282-7

Cheng, 2014, beta-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 mice through CB2 receptor activation and the PPARgamma pathway, Pharmacology., 94, 1, 10.1159/000362689

Liu, 2016, Curcumin attenuates beta-amyloid-induced neuroinflammation via activation of peroxisome proliferator-activated receptor-gamma function in a rat model of Alzheimer's disease, Front. Pharmacol., 7, 261, 10.3389/fphar.2016.00261

Song, 2016, Cyanidin 3-O-beta-glucopyranoside activates peroxisome proliferator-activated receptor-gamma and alleviates cognitive impairment in the APP(swe)/PS1(DeltaE9) mouse model, Biochim. Biophys. Acta., 1862, 1786, 10.1016/j.bbadis.2016.05.016

Bonet-Costa, 2016, Clearing amyloid-beta through PPARgamma/ApoE activation by genistein is a treatment of experimental Alzheimer's disease, J. Alzheimers Dis., 51, 701, 10.3233/JAD-151020

Inestrosa, 2013, Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease, J. Alzheimers Dis., 33, 941, 10.3233/JAD-2012-120397

Tong, 2016, T3D-959: a multi-faceted disease remedial drug candidate for the treatment of Alzheimer's disease, J. Alzheimers Dis., 51, 123, 10.3233/JAD-151013

Dumont, 2012, Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice, Hum. Mol. Genet., 21, 5091, 10.1093/hmg/dds355

Kummer, 2015, Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits, Mol. Neurobiol., 51, 661, 10.1007/s12035-014-8743-4

Jiang, 2008, The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications, CNS Drugs., 22, 1, 10.2165/00023210-200822010-00001

Donkin, 2010, ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice, J. Biol. Chem., 285, 34144, 10.1074/jbc.M110.108100

Wesson, 2011, Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's beta-amyloidosis mouse model, J. Neurosci., 31, 15962, 10.1523/JNEUROSCI.2085-11.2011

Riddell, 2007, The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease, Mol. Cell. Neurosci., 34, 621, 10.1016/j.mcn.2007.01.011

Lefterov, 2007, Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment, Mol. Neurodegener., 2, 20, 10.1186/1750-1326-2-20

Fitz, 2010, Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice, J. Neurosci., 30, 6862, 10.1523/JNEUROSCI.1051-10.2010

Vanmierlo, 2011, Liver X receptor activation restores memory in aged AD mice without reducing amyloid, Neurobiol. Aging., 32, 1262, 10.1016/j.neurobiolaging.2009.07.005

Cui, 2012, Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice, Neuroscience., 210, 200, 10.1016/j.neuroscience.2012.02.047

Fitz, 2014, Improvement of memory deficits and amyloid-beta clearance in aged APP23 mice treated with a combination of anti-amyloid-beta antibody and LXR agonist, J. Alzheimers Dis., 41, 535, 10.3233/JAD-132789

Hu, 2013, Synthesis and identification of new flavonoids targeting liver X receptor beta involved pathway as potential facilitators of Abeta clearance with reduced lipid accumulation, J. Med. Chem., 56, 6033, 10.1021/jm301913k

Stachel, 2016, Identification and in vivo evaluation of liver X receptor beta-selective agonists for the potential treatment of Alzheimer's disease, J. Med. Chem., 59, 3489, 10.1021/acs.jmedchem.6b00176

Price, 2013, Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”, Science., 340, 924-d, 10.1126/science.1234089

Fitz, 2013, Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”, Science., 340, 924-c, 10.1126/science.1235809

Veeraraghavalu, 2013, Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”, Science., 340, 924-f, 10.1126/science.1235505

Tesseur, 2013, Comment on “ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models”, Science., 340, 924-e, 10.1126/science.1233937

Ulrich, 2013, In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis, Mol. Neurodegener., 8, 13, 10.1186/1750-1326-8-13

LaClair, 2013, Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice, Mol. Neurodegener., 8, 18, 10.1186/1750-1326-8-18

Tai, 2014, Amyloid-beta pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo, J. Biol. Chem., 289, 30538, 10.1074/jbc.M114.600833

Casali, 2015, Omega-3 fatty acids augment the actions of nuclear receptor agonists in a mouse model of Alzheimer's disease, J. Neurosci., 35, 9173, 10.1523/JNEUROSCI.1000-15.2015

Corona, 2016, ABCA1 is necessary for bexarotene-mediated clearance of soluble amyloid beta from the hippocampus of APP/PS1 mice, J. Neuroimmune Pharmacol., 11, 61, 10.1007/s11481-015-9627-8

Kawahara, 2014, Cooperative therapeutic action of retinoic acid receptor and retinoid X receptor agonists in a mouse model of Alzheimer's disease, J. Alzheimers Dis., 42, 587, 10.3233/JAD-132720

Kitaoka, 2013, The retinoic acid receptor agonist Am80 increases hippocampal ADAM10 in aged SAMP8 mice, Neuropharmacology., 72, 58, 10.1016/j.neuropharm.2013.04.009

Tippmann, 2009, Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin, FASEB J., 23, 1643, 10.1096/fj.08-121392

Ding, 2008, Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model, J. Neurosci., 28, 11622, 10.1523/JNEUROSCI.3153-08.2008